Special thanks to

Shire
Genzyme

The full article and its related educational material were produced by and under the sole responsibility of the Working Group on Myocardial and Pericardial Diseases.
ESC WORKING GROUP ON MYOCARDIAL AND PERICARDIAL DISEASES: 
KEY MESSAGES on Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis 

Table of contents

1. Introduction and scope of the document.................................................................Page 3
2. Definitions.............................................................................................................Page 4
3. Causes..................................................................................................................Page 6
4. Pathogenetic mechanisms.....................................................................................Page 11
5. Clinical presentations of patients with biopsy-proven disease............................Page 17
6. Diagnosis.............................................................................................................Page 19
   6.1 First line tests (ECG, echocardiography, nuclear imaging, Cardiovascular Magnetic Resonance (CMR) imaging, biomarkers).................................................Page 21
   6.2 Proposed criteria for clinically suspected myocarditis....................................Page 26
   6.3 Second line investigations for clinically suspected myocarditis: EndoMyocardial Biopsy (EMB)...............................................................Page 28
7. Clinical management
   7.1 1. Prognostic factors, 2. Conventional medical treatment (Haemodynamically unstable patients, haemodynamically stable patients, arrhythmia, avoidance of exercise)........................................Page 33
   7.2 Immunomodulatory therapy (Antiviral therapy, high dose intravenous immunoglobulin, ImmunoAdsorption (IA))..................................................................................Page 36
   7.3 Immunosuppressive therapy............................................................................Page 37
8. Follow-up: recommendations.............................................................................Page 40
I. Introduction and scope of the document
Myocarditis is a challenging diagnosis due to the heterogeneity of clinical presentations. The actual incidence of myocarditis is difficult to determine as endomyocardial biopsy (EMB), the diagnostic gold standard, is used infrequently.

Studies on sudden cardiac death in young people report a highly variable autopsy prevalence of myocarditis, ranging from 2 to 42%. EMB-proven myocarditis is reported in 9–16% of adult patients with unexplained non-ischaemic dilated cardiomyopathy (DCM) and in 46% of children with an identified cause of DCM.

In patients presenting with mild symptoms and minimal ventricular dysfunction, myocarditis often resolves spontaneously without specific treatment. In up to 30% of cases, EMB-proven myocarditis can progress to DCM and is associated with a poor prognosis. Prognosis in myocarditis patients varies according to the underlying aetiology.

The treatment of many forms of myocarditis is symptomatic, but immunohistochemical and molecular biological analysis of EMB as well as autoantibody serum testing is important to identify those patients in whom specific therapy is appropriate.

In this Position Statement, an expert consensus group has reviewed the current literature on clinical presentation, diagnosis, and treatment of myocarditis and propose new diagnostic criteria for clinically suspected myocarditis. The aims are to bridge the gap between clinical and tissue-based diagnosis, to improve management and provide a common reference point for future registries and multicentre randomised controlled trials of aetiology driven treatment in inflammatory heart muscle disease.
2. Definitions
In this document, we recommend use of existing definitions of myocarditis and inflammatory cardiomyopathy (Box 1), but acknowledge that there is some confusion about the terms DCM and inflammatory cardiomyopathy. Dilated cardiomyopathy is a clinical diagnosis based on morphological and functional characterization of the left ventricle; inflammatory cardiomyopathy is both a histological and functional diagnosis characterized by myocarditis in association with systolic and/or diastolic cardiac dysfunction; thus inflammatory cardiomyopathy and DCM are not mutually exclusive.

The histological diagnosis of myocarditis includes different forms, classified according to the type of inflammatory cell infiltrate: lymphocytic, eosinophilic, polymorphic, giant cell myocarditis, and cardiac sarcoidosis. The task group also recommends the following criteria for subsets of myocarditis or inflammatory cardiomyopathy:

- **Infectious myocarditis**
  Histological evidence for myocarditis and positive polymerase chain reaction (RT-PCR) for cardiotropic agents, especially viruses on EMB (Table 1).

- **Autoimmune myocarditis**
  Histological myocarditis with negative viral PCR, with or without serum cardiac autoantibodies (aabs) (Table 2). N.B. There are autoimmune diseases (e.g. Hashimoto’s thyroiditis) where aabs are mainly biomarkers, autoantibody-mediated forms (e.g. Graves’ disease), in which aabs are pathogenic, and cell-mediated autoimmune diseases, which are negative for aabs. In all cases, autoimmune diseases are negative for infectious agents.
• **Viral and immune myocarditis**

Histological myocarditis with positive viral PCR and positive cardiac aabs (Table 2).

N.B. A follow-up EMB may document persistent viral myocarditis, histological and virological resolution, or persistent virus-negative myocarditis, with or without serum cardiac aabs, e.g. post-infectious autoimmune disease.

**BOX 1 Definitions**

**Myocarditis (WHO /ISFC):**

Inflammatory disease of the myocardium diagnosed by established histological*, immunological and immunohistochemical criteria**.

* N.B. established histological Dallas criteria defined as follows: ‘histological evidence of inflammatory infiltrates within the myocardium associated with myocyte degeneration and necrosis of nonischaemic origin.

** N.B. unspecified immunohistochemical criteria, we propose an abnormal inflammatory infiltrate to be defined as follows: ‘≥4 leucocytes/mm² including up to 4 monocytes/mm² with the presence of CD3-positive T-lymphocytes ≥7 cells/mm²’.

**Inflammatory Cardiomyopathy (WHO /ISFC):**

Myocarditis in association with cardiac dysfunction.

N.B. Inflammatory cardiomyopathy, involved in the pathogenesis of DCM, includes idiopathic, autoimmune and infectious subtypes.

**Dilated Cardiomyopathy (ESC; WHO /ISFC):**

DCM is a clinical diagnosis characterized by dilation and impaired contraction of the left or both ventricles that is not explained by abnormal loading conditions or coronary artery disease.

*N.B. DCM includes idiopathic, familial/genetic, viral and/or immune, alcoholic/toxic subtypes.
3. Causes of myocarditis/inflammatory cardiomyopathy

Although the aetiology of myocarditis often remains undetermined, a large variety of infectious agents, systemic diseases, drugs, and toxins can cause the disease (Table 1).

Some causes of myocarditis are now largely historical or occur in very specific scenarios such as sepsis or in immunocompromised patients. Molecular techniques, mainly (reverse transcriptase) (RT)-PCR amplification, suggest that viral infections are the most important cause of myocarditis in North America and Europe with genomes of enteroviruses, adenoviruses, influenza viruses, human herpes virus-6 (HHV-6), Epstein-Barr-virus, cytomegalovirus, hepatitis C virus, and parvovirus B19 reported in the myocardium of patients with myocarditis and DCM.

Lymphocytic and giant cell myocarditis are presumed idiopathic or autoimmune if no viruses are identified in EMB and other known causes are excluded (Figures 1a and 1b).

Similarly, the diagnosis of idiopathic granulomatous myocarditis (cardiac sarcoidosis) requires negative stains for microorganisms. Autoimmune myocarditis may occur with exclusive cardiac involvement or in the context of autoimmune disorders with extra-cardiac manifestations, most frequently in sarcoidosis (Figures 1a and 1b), hypereosinophilic syndrome, scleroderma, and systemic lupus erythematosus.
Figure 1a
Histopathology and immunopathology of acute lymphocytic myocarditis (first row, X100), chronic lymphocytic myocarditis (second row, X200), sarcoidosis (third row, X100), and giant cell myocarditis (fourth row, X200). Left column: haematoxylin-eosin (HE); middle column: staining with anti-CD3 antibody (pan T lymphocyte marker); right column: staining with anti-CD68 antibody (macrophage marker).
Figure 1b
Short-axis (upper line) and long-axis (lower line) CMR images of a young patient with acute myocarditis. In the first two columns, cine-SSFP images are shown in diastole and systole and suggest absence of any wall motion abnormality. In the next column, T2-weighted edema images demonstrate the presence of patchy focal edema in the subepicardium of the inferolateral wall (red arrows). In the last column, T1-weighted LGE images demonstrate presence of subepicardially distributed LGE (red arrows) which is typical for acute myocarditis.
# Table 1 Causes of myocarditis/inflammation cardiomyopathy

## 1. Infectious myocarditis

**Bacterial**  
*Staphylococcus*, *Streptococcus*, *Pneumococcus*, *Meningococcus*, *Gonococcus*, *Salmonella*, *Corynebacterium diphtheriae*, *Haemophilus influenzae*, *Mycobacterium* (tuberculosis), *Mycoplasma pneumoniae*, *Brucella*

**Spirochaetal**  
*Borrelia* (Lyme disease), *Leptospira* (Weil disease)

**Fungal**  
*Aspergillus*, *Actinomyces*, *Blastomyces*, *Candida*, *Coccidioides*, *Cryptococcus*, *Histoplasma*, *Mucormycoses*, *Nocardia*, *Sporothrix*

**Protozoal**  
*Trypanosoma cruzi*, *Toxoplasma gondii*, *Entamoeba*, *Leishmania*

**Parasitic**  
*Trichinella spiralis*, *Echinococcus granulosus*, *Taenia solium*

**Rickettsial**  
*Coxiella burnetii* (Q fever), *R. rickettsii* (Rocky Mountain spotted fever), *R. tsutsugamushi*

**Viral**  
RNA viruses: Coxsackieviruses A and B, echoviruses, polioviruses, influenza A and B viruses, respiratory syncytial virus, mumps virus, measles virus, rubella virus, hepatitis C virus, dengue virus, yellow fever virus, Chikungunya virus, Junin virus, Lassa fever virus, rabies virus, human immunodeficiency virus-1  
DNA viruses: adenoviruses, parvovirus B19, cytomegalovirus, human herpes virus-6, Epstein-Barr virus, varicella-zoster virus, herpes simplex virus, variola virus, vaccinia virus

## 2. Immune-mediated myocarditis

**Allergens**  
Tetanus toxoid, vaccines, serum sickness  
Drugs: penicillin, cefaclor, colchicine, furosemide, isoniazid, lidocaine, tetracycline, sulfonamides, phenytoin, phenylbutazone, methyldopa, thiazide diuretics, amitriptyline

**Alloantigens**  
Heart transplant rejection
<table>
<thead>
<tr>
<th><strong>Table 1 Causes of myocarditis/inflammation cardiomyopathy (continued)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2. Immune-mediated myocarditis</strong></td>
</tr>
</tbody>
</table>
| **Autoantigens** | Infection-negative lymphocytic, infection-negative giant cell  
Associated with autoimmune or immune-oriented disorders: systemic lupus erythematosus, rheumatoid arthritis, Churg-Strauss syndrome, Kawasaki’s disease, inflammatory bowel disease, scleroderma, polymyositis, myasthenia gravis, insulin-dependent diabetes mellitus, thyrotoxicosis, sarcoidosis, Wegener’s granulomatosis, rheumatic heart disease (rheumatic fever) |
| **3. Toxic myocarditis** |
| **Drugs** | Amphetamines, anthracyclines, cocaine, cyclophosphamide, ethanol, fluorouracil, lithium, catecholamines, hemetine, interleukin-2, trastuzumab, clozapine |
| **Heavy metals** | Copper, iron, lead (rare, more commonly cause intramyocyte accumulation) |
| **Miscellaneous** | Scorpion sting, snake, and spider bites, bee and wasp stings, carbon monoxide, inhalants, phosphorus, arsenic, sodium azide |
| **Hormones** | Phaeochromocytoma, vitamins: beri–beri |
| **Physical agents** | Radiation, electric shock |
4. Pathogenetic mechanisms

In human myocarditis, there is evidence for viral and autoimmune mechanisms, acting in individuals with or without a genetic predisposition (familial or sporadic cases, respectively). Murine studies of viral myocarditis are based mostly on coxsackievirus B3-infected animals, which exhibit strain-specific susceptibility.

Enteroviruses that preferentially enter cardiomyocytes via specific receptors cause severe cytopathic effects due to virus replication in the first 2 weeks post-infection. As a consequence, a humoral and cellular immune response, mainly consisting of macrophages and CD4+ and CD8+ T- lymphocytes, is initiated in resistant animals and leads to the elimination of the infectious agent within 2 weeks following infection. In susceptible mouse strains (e.g. A/J, Balb/c), viral RNA and inflammation persist in the heart for several weeks. In these susceptible mice strains, the ongoing infection and inflammation trigger autoimmune reactions in the heart, most likely as a result of myocyte necrosis and subsequent release of self-antigens previously hidden to the immune system (Figure 2).

The same genetically predisposed strains of animals develop autoimmune lymphocytic or giant cell myocarditis and later DCM after immunization with cardiac autoantigens (e.g. cardiac myosin) or spontaneously. In common with other autoimmune diseases, major histocompatibility complex (MHC) and non-MHC genes appear to be responsible for the predisposition to murine and human myocarditis or DCM. Progression from myocarditis to DCM seems to occur predominantly in patients with histologically confirmed persistent (chronic) inflammation that cannot eliminate the infective microbial agents or have developed pathogenic cardiac autoantibodies directed against myocardial structural, sarcoplasmic, or sarcolemmal proteins. The frequency, cardiac, and disease specificity for such antibodies in myocarditis/DCM are summarized in Table 2.
**Genetic Background**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbial infection</td>
<td>Non-infectious</td>
<td></td>
</tr>
<tr>
<td>(viruses, bacteria, fungi, etc.)</td>
<td>(drugs, toxins, venoms, SLE, sarcoidosis, unknown antigens)</td>
<td></td>
</tr>
</tbody>
</table>

**Phase I**

- Direct microbial damage
- Direct/indirect toxic damage
- Exposure of normally hidden antigens to the immune system or antigen mimikry
- Myocyte death, release of chemokines/cytokines
- Activation of the immune system

**Acute Myocarditis**

- Activation of cross- or autoreactive T cells, induction of autoantibodies
Genetic Background

Acute Myocarditis

Autoreactive myocarditis

Chronic myocarditis

Chronic microbial myocarditis

Chronic microbial & immune myocarditis

Chronic autoreactive myocarditis

Dilated cardiomyopathy

Microbial infection (viruses, bacteria, fungi, etc.)

Direct microbial damage

Direct/indirect toxic damage

Exposure of normally hidden antigens to the immune system or antigen mimicry

Activation of cross- or autoreactive T cells, induction of autoantibodies

• Microbial agents eliminated
  • Resolution of inflammation

• Microbial agents present
  • Ongoing inflammation

• No microbial agents or drugs
  • Ongoing inflammation

• Microbial agents present or not
  • Autoantibodies present or not
  • No florid inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • Autoantibodies present
  • Ongoing inflammation
  • Ongoing destruction/remodeling

• Microbial agents present or not
  • Autoantibodies present
  • Ongoing inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • Autoantibodies present or not
  • No florid inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • Ongoing inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • No florid inflammation
  • Ongoing destruction/remodeling

Pathogen Phase 1 Phase II Phase III

Non-infectious (drugs, toxins, venoms, SLE, sarcoidosis, unknown antigens)

Healed myocarditis

Chronic myocarditis

• Myocyte death, release of chemokines/cytokines
  • Activation of the immune system

• Microbial agents eliminated
  • Resolution of inflammation

• Microbial agents present
  • Ongoing inflammation

• No microbial agents or drugs
  • Ongoing inflammation

• Microbial agents present or not
  • Autoantibodies present or not
  • No florid inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • Autoantibodies present
  • Ongoing inflammation
  • Ongoing destruction/remodeling

• Microbial agents present or not
  • Autoantibodies present
  • Ongoing inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • Ongoing inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • No florid inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • No florid inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • No florid inflammation
  • Ongoing destruction/remodeling

• No microbial agents
  • No autoantibodies
  • No florid inflammation
  • Ongoing destruction/remodeling
Table 2 Serum cardiac autoantibodies in autoimmune myocarditis/dilated cardiomyopathy: frequency in myocarditis/dilated cardiomyopathy, other cardiac disease (OCD) and normals

<table>
<thead>
<tr>
<th>Cardiac autoantibody (Ab)</th>
<th>% aabs positive</th>
<th>% antibody positive</th>
<th>Functional effect/clinical relevance</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Myoc DCM OCD Normal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle-specific ASA, (AFA,IFA,AMLA)</td>
<td>28–59* 9–41* NT 0–25</td>
<td>Myocytolysis</td>
<td>72, 77, 57, 64</td>
<td></td>
</tr>
<tr>
<td>Cardiac-specific AHA AIDA</td>
<td>41–56*^,a 17*^,a</td>
<td>26–30*^,a 16*^,a</td>
<td>1–4 2–4 3</td>
<td>Cardiac- and disease-specific early predictors; predict DCM development in relatives</td>
</tr>
<tr>
<td>Anti-Beta1-AR</td>
<td>33 NT 73–96*^,a NT</td>
<td>40–51^ 35*^,a, 29–95*^,a 27–28</td>
<td>13–55 16 8 10</td>
<td>Negative predictors, pro-apoptotic and other in vitro effects^b</td>
</tr>
<tr>
<td>Anti-Beta2-AR</td>
<td>NT NT NT</td>
<td>30–38^ 13–14 30–75^a</td>
<td>33 37</td>
<td>Association with idiopathic arrhythmia</td>
</tr>
<tr>
<td>Anti-muscarinic acetylcholine receptor-2</td>
<td>II NT</td>
<td>30–77^c 83^c</td>
<td>23d–61 8–13</td>
<td>Negative inotropic, muscarinic effects Association with atrial arrhythmia</td>
</tr>
<tr>
<td>Cardiodepressant (Fg-gamma-receptor 2a)</td>
<td>NT</td>
<td>64</td>
<td>Negative inotropic effects in rat and rat and human myocytes in vitro</td>
<td>56, 66^l, 85–87, 91^l</td>
</tr>
</tbody>
</table>

^a^Experimental model: rat and human myocytes in vitro
^b^Cardiac transplanter model
<table>
<thead>
<tr>
<th>Cardiac autoantibody (Ab)</th>
<th>% aabs positive</th>
<th>% antibody positive</th>
<th>Functional effect/clinical relevance</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Ky channel-interacting protein 2, KChIP2.6—ELISA</td>
<td>NT</td>
<td>14^</td>
<td>Increased cell death in myocytes in vitro</td>
<td></td>
</tr>
<tr>
<td>Anti-Alpha-MHC (cardiac-specific)</td>
<td>17–37^,^,a</td>
<td>20–46^,^,a</td>
<td>Negative predictors, pro-apoptotic</td>
<td>109, 51^a, 60^a, 118^a, 140^a</td>
</tr>
<tr>
<td>Anti-Beta-MHC (muscle-cross reactive)</td>
<td>NT</td>
<td>55^</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-MLC Iν</td>
<td>NT</td>
<td>17–35</td>
<td>0–15</td>
<td>51, 67^</td>
</tr>
<tr>
<td>Anti-tropomyosin</td>
<td>NT</td>
<td>55^</td>
<td></td>
<td>67</td>
</tr>
<tr>
<td>Anti-non-myofibrillar</td>
<td>NT</td>
<td>46^,^,a</td>
<td>0</td>
<td>51^a</td>
</tr>
<tr>
<td>Anti-MHC</td>
<td>NT</td>
<td>67^</td>
<td></td>
<td>67</td>
</tr>
<tr>
<td>Anti-actin</td>
<td>NT</td>
<td>71^</td>
<td></td>
<td>67</td>
</tr>
<tr>
<td>Anti-Troponin I ,T</td>
<td>NT</td>
<td>1.7–20^</td>
<td>0^–18</td>
<td>66, 68, 80</td>
</tr>
<tr>
<td>Anti-laminin</td>
<td>73</td>
<td>78</td>
<td>25–35</td>
<td>97</td>
</tr>
<tr>
<td>Anti-HSP60,70</td>
<td>NT</td>
<td>10–85^</td>
<td>1–42</td>
<td>67, 79</td>
</tr>
<tr>
<td>Anti-s.Na/K-ATPase</td>
<td>26^</td>
<td>NT</td>
<td>2</td>
<td>49</td>
</tr>
</tbody>
</table>
Table 2 Serum cardiac autoantibodies in autoimmune myocarditis/dilated cardiomyopathy: frequency in myocarditis/dilated cardiomyopathy, other cardiac disease (OCD) and normals (continued)

<table>
<thead>
<tr>
<th>Cardiac autoantibody (Ab)</th>
<th>% aabs positive</th>
<th>% antibody positive</th>
<th>Functional effect/clinical relevance</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Myoc</td>
<td>DCM</td>
<td>OCD</td>
<td>Normal</td>
</tr>
<tr>
<td>Anti- ANT</td>
<td>91*:^,a</td>
<td>57*:^,a</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anti-M7</td>
<td>13*</td>
<td>31*</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Anti-BCKD-E2</td>
<td>100*^</td>
<td>60*^</td>
<td>4</td>
<td>0</td>
</tr>
</tbody>
</table>

*P, 0.05 vs. normals; ^P, 0.05 vs. OCD.

AFA, anti-fibrillary Ab; AHA, organ-specific and partially organ-specific anti-heart aabs; AIDA, anti-intercalated disks-aabs; ANT, adenine nucleotide translocator; AMLA, anti-myolemmal aabs; AR, adrenergic receptor; ASA, anti-sarcolemmal aabs; IFA, anti-interfibrillary aabs; BCKD, branched chain alpha-ketoacid dehydrogenase dihydrolipoyl transacylase; HSP, heat shock protein; NT, not tested; OCD, other cardiac disease; MHC, myosin heavy chain; MLC1v, myosin light chain I ventricular; Myoc, myocarditis.

^Cardiac and disease-specific for myocarditis/DCM. - Increase L-type Ca2+ current; short-term positive inotropic effects; increase in cytoplasmic cAMP, and cAMP/FRET-activity. - 77% (in Chagas-DCM). - In atrial fibrillation patients. - In selected ELISA-positive heart failure patients.

For Reference list and numbering in Table 2 go to:

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Eur Heart J. 2013 Sep;34(33):2636-48
5. Clinical presentations of patients with biopsy-proven disease
Myocarditis presents in many different ways, ranging from mild symptoms of chest pain and palpitations associated with transient ECG changes to life-threatening cardiogenic shock and ventricular arrhythmia (Table 3). The disease may affect individuals of all ages, although it is most frequent in the young.

This diversity of clinical scenarios implies that the diagnosis requires a high level of suspicion early in the course of the disease and the use of appropriate investigations to identify its cause. In all cases of suspected myocarditis, it is mandatory to exclude coronary artery disease and other cardiovascular, e.g. hypertension, or extra-cardiac non-inflammatory diseases that could explain the clinical presentation.

Rarely patients with other cardiovascular disorders such as coronary artery disease, cardiomyopathy, and hypertensive heart disease present with a clinical deterioration caused by myocarditis that is mistakenly attributed to the natural history of the preexisting disease. If this is strongly suspected by the clinician, further investigation including EMB may be appropriate.

Myocarditis can be an incidental finding in autopsy studies of individuals who died of non-cardiac death or in myocardial samples obtained for clinical reasons unrelated to the clinical suspicion of myocarditis, for example following valve surgery or in explanted hearts taken from patients that have received inotropic drugs. In these circumstances, the significance of myocardial inflammation must be interpreted cautiously in the light of the clinical scenario.
<table>
<thead>
<tr>
<th>Table 3 Clinical presentations of patients with biopsy-proven inflammatory heart muscle disease</th>
</tr>
</thead>
</table>

**(1) Acute coronary syndrome-like**

(a) Acute chest pain
- Frequently starting within 1–4 weeks of a respiratory or gastrointestinal infection
- Frequently associated with severe and recurrent symptoms
- In the absence of angiographic evidence of CAD

(b) ST/T wave changes
- ST-segment elevation or depression
- T-wave inversions

(c) With or without normal global or regional LV and/or RV dysfunction on echocardiography or CMR

(d) With or without increased TnT/TnI that may have a time course similar to acute myocardial infarction or a prolonged and sustained release over several weeks or months

**(2) New onset or worsening heart failure in the absence of CAD and known causes of heart failure**

(a) New onset or progressive heart failure over 2 weeks to 3 months
- Dyspnoea
- Peripheral oedema
- Chest discomfort
- Fatigue

(b) Impaired systolic LV and/or RV function, with or without an increase in wall thickness, with or without dilated LV and/or RV on echocardiography or CMR

(c) Symptoms possibly started after a respiratory or gastrointestinal infection, or in the peri-partum period

(d) Non-specific ECG signs, bundle branch block, AV-block, and/or ventricular arrhythmias
6. Diagnosis

Non-invasive imaging techniques such as cardiac magnetic resonance (CMR) imaging can be useful in making the diagnosis of myocarditis and for monitoring disease progression, but we strongly endorse the concept that EMB should be the gold standard for the diagnosis of definite myocarditis.

However, this implies that all patients with suspected myocarditis should undergo an EMB which is not routine practice; moreover, current guidelines recommend EMB only in a limited number of clinical scenarios that do not include some common presentations of myocarditis, in particular, pseudo-infarction.

In order to improve recognition of myocarditis in clinical practice and to aid selection of patients that require further diagnostic evaluation and treatment, we propose new criteria for clinically suspected myocarditis for which biopsy is recommended (Table 4).

Table 3 Clinical presentations of patients with biopsy-proven inflammatory heart muscle disease (continued)

| (3) Chronic heart failure in the absence of CAD and known causes of heart failure (see point 2 above) |
| (a) Heart failure symptoms (with recurrent exacerbations) of ≥3 months duration |
| (b) Fatigue, palpitation, dyspnoea, atypical chest pain, arrhythmia in an ambulant patient |
| (c) Impaired systolic LV and/or RV function on echocardiography or CMR suggestive of DCM or non-ischaemic cardiomyopathy |
| (d) Non-specific ECG signs, sometimes bundle branch block and/or ventricular arrhythmias and/or AV-block |

| (4) ‘life-threatening condition’, in the absence of CAD and known causes of heart failure comprising |
| (a) Life-threatening arrhythmias and aborted sudden death |
| (b) Cardiogenic shock |
| (c) Severely impaired LV function |
These criteria are based upon consensus of experts and require validation in future multicentre registries and randomized trials in patients who have undergone EMB. Medical centres that cannot safely perform EMB or do not have access to state-of-the-art CMR should refer patients with clinically suspected myocarditis to a tertiary referral unit experienced in EMB and CMR, particularly when patients present with haemodynamic instability or life-threatening arrhythmia.

Table 4 Diagnostic criteria for clinically suspected myocarditis

<table>
<thead>
<tr>
<th>Clinical presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Acute chest pain, pericarditic, or pseudo-ischaemic</td>
</tr>
<tr>
<td>• New-onset (days up to 3 months) or worsening of: dyspnoea at rest or exercise, and/or fatigue, with or without left and/or right heart failure signs</td>
</tr>
<tr>
<td>• Subacute/chronic (&gt;3 months) or worsening of: dyspnoea at rest or exercise, and/or fatigue, with or without left and/or right heart failure signs</td>
</tr>
<tr>
<td>• Palpitation, and/or unexplained arrhythmia symptoms and/or syncope, and/or aborted sudden cardiac death</td>
</tr>
<tr>
<td>• Unexplained cardiogenic shock</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. ECG/Holter/stress test features</td>
</tr>
<tr>
<td>Newly abnormal 12 lead ECG and/or Holter and/or stress testing, any of the following: I to III degree atrioventricular block, or bundle branch block, ST/T wave change (ST elevation or non ST elevation, T wave inversion), sinus arrest, ventricular tachycardia or fibrillation and asystole, atrial fibrillation, reduced R wave height, intraventricular conduction delay (widened QRS complex), abnormal Q waves, low voltage, frequent premature beats, supraventricular tachycardia</td>
</tr>
</tbody>
</table>

| II. Myocardiocytolysis markers |
| Elevatet TnT/TnI |
6.1. First line tests in patients with a clinical presentation consistent with myocarditis

6.1.1 Electrocardiogram (ECG)

Electrocardiogram (ECG) is usually abnormal in myocarditis though ECG signs are neither specific nor sensitive (Table 4). Some ECG changes are more suggestive of myocarditis than others. For example, ST-T segment elevation in myocarditis is typically concave (rather than convex in myocardial ischaemia) and diffuse without reciprocal changes. A-V block in the presence of mild left ventricular dilatation can be due to various causes (including laminopathy), but it may also be suggestive of Lyme disease, cardiac sarcoidosis, or giant cell myocarditis. In recent studies, QRS prolongation was an independent negative predictor for survival (which could be also due solely to asynchrony in left bundle branch block), while Q-waves and repolarization abnormalities were unrelated to the outcome or immunohistological features of inflammation on EMB.
**Recommendation**

1. Standard 12-lead electrocardiogram should be performed in all patients with clinically suspected myocarditis.

**6.1.2 Echocardiography**

Echocardiography helps to rule out non-inflammatory cardiac disease, such as valve disease, and to monitor changes in cardiac chamber size, wall thickness, ventricular function, and pericardial effusion. Global ventricular dysfunction, regional wall motion abnormalities, and diastolic dysfunction with preserved ejection fraction may occur in myocarditis. Histologically proven myocarditis may resemble dilated, hypertrophic, and restrictive cardiomyopathy and can mimic ischaemic heart disease. Fulminant myocarditis often presents with a non-dilated, thickened, and hypocontractile left ventricle as the intense inflammatory response results in interstitial oedema and loss of ventricular contractility. The role of newer imaging techniques such as strain-rate imaging remains to be determined.

**Recommendations**

2. All patients with clinically suspected myocarditis should undergo a standard trans-thoracic echocardiogram at presentation.

3. Trans-thoracic echocardiogram should be repeated during hospitalization if there is any worsening of haemodynamics.

**6.1.3 Nuclear imaging**

Data on radionuclide evaluation, including antimyosin antibody imaging, are scarce but suggest that its sensitivity for detecting myocardial inflammation is variable and its specificity low. Due to their limited availability and risk from radiation exposure, nuclear techniques are not routinely recommended for the diagnosis of myocarditis, with the possible exception of sarcoidosis. Thallium 201 and technetium 99m scintigraphy have been used to detect cardiac
sarcoidosis but lack specificity. Gallium-67 scintigraphy and more recently positron emission tomography using F-18 fluorodeoxyglucose are probably more sensitive and may be useful in the acute phase of sarcoidosis and to monitor disease progression. The detection of extracardiac disease can suggest a diagnosis of cardiac sarcoidosis.

**Recommendations**

4. Nuclear imaging is not routinely recommended in the diagnosis of myocarditis, with the possible exception of suspected cardiac sarcoidosis.

6.1.4 Cardiovascular magnetic resonance (CMR) imaging

CMR imaging provides non-invasive tissue characterization of the myocardium and can support the diagnosis of myocarditis (Figure 1). The timing of CMR in suspected myocarditis will depend upon local availability and expertise, but it is reasonable to first perform CMR in clinically stable patients, prior to EMB. It should not be performed in lifethreatening presentations where EMB is urgently indicated. Based on pre-clinical and clinical studies, an ‘International Consensus Group on CMR Diagnosis of Myocarditis’ published detailed recommendations on the indication, implementation, and analysis of appropriate CMR techniques for non-invasive diagnosis of myocarditis (Lake Louise criteria). The combined use of three different CMR techniques is suggested (Table 5). Correlation between CMR and EMB is worse in histologically confirmed chronic myocarditis. CMR cannot identify viral or other infectious causes.

**Recommendations**

5. CMR findings consistent with myocarditis should be based on Lake-Louise criteria (Table 5).

6. CMR may be considered in clinically stable patients prior to EMB. CMR does not replace EMB in the diagnosis of myocarditis and should not delay EMB in life-threatening presentations.
Global signal intensity (SI) increase has to be quantified by an SI ratio of myocardium over skeletal muscle of ≥2.0. If the edema is more subendocardial or transmural in combination with a colocalized ischaemic (including the subendocardial layer) pattern of late gadolinium enhancement, acute myocardial infarction is more likely and should be reported. -

A global SI enhancement ratio of myocardium over skeletal muscle of ≥4.0 or an absolute myocardial enhancement of ≥45% is consistent with myocarditis. -

Images should be obtained at least 5 min after gadolinium injection; foci typically exclude the subendocardial layer, are often multifocal, and involve the subepicardium. If the late gadolinium enhancement pattern clearly indicates myocardial infarction and is colocalized with a transmural regional edema, acute myocardial infarction is more likely and should be reported.

For Reference list and numbering in Table 5 go to:
6.1.5 Biomarkers

a) Inflammatory markers
Erythrocyte sedimentation rate and reactive C protein levels are often raised in myocarditis, but they do not confirm the diagnosis and are often increased in acute pericarditis.

b) Troponin and BNP levels
While cardiac troponins are more sensitive of myocyte injury in patients with clinically suspected myocarditis than creatine kinase levels, they are non-specific and when normal, do not exclude myocarditis. This also applies to cardiac hormones such as brain natriuretic peptides, circulating cytokines, markers related to extracellular matrix degradation, and new biomarkers such as pentraxin 3, galectin 3, and growth differentiation factor.

c) Viral antibodies
Positive viral serology does not imply myocardial infection but rather indicates the interaction of the peripheral immune system with an infectious agent. Thus, viral serology is of limited utility in the diagnosis of viral myocarditis because the prevalence of circulatory IgG antibodies to cardiotropic viruses in the general population is high in the absence of viral heart disease. In addition, infection with non-cardiotropic enteroviruses may cause an antibody response which is indistinguishable from the response to cardiotropic viruses. Circumstances in which serological testing may be helpful include suspected infection with hepatitis C virus, HIV in high-risk patients, rickettsia (phase 1 and 2), borrelia (Lyme disease in endemic areas,

d) Serum cardiac autoantibodies (aabs)
Aabs to various cardiac and muscle-specific autoantigens are found in myocarditis and in DCM patients (Table 2). Lack of viral genome in EMB with detectable serum aabs suggests immune-mediated DCM or myocarditis. Antibodies of IgG class, which are shown to be cardiac and disease-specific for myocarditis/DCM, can be used
as autoimmune biomarkers for identifying at risk relatives and those patients in whom, in the absence of active infection of the myocardium, immunosuppression and/or immunomodulation may be beneficial. Detection of cardiodepressant antibodies in DCM also predicts haemodynamic benefits from immunoabsorption. Some aabs have been described to be negative predictors in myocarditis or DCM (Table 2). At present, no commercially available cardiac autoantibody tests have been validated against the results obtained in research laboratories.

Recommendations
7. Troponins, erythrocyte sedimentation rate, reactive C protein levels should be assessed in all patients.
8. Routine viral serology testing is not recommended.
9. Serum samples should be assessed, if possible, for cardiac aabs, if one (or more) of the published tests is available (Table 2), according to specific centre expertise. Disease-specific aabs should preferably be tested.

6.2. Proposed criteria for clinically suspected myocarditis
Myocarditis should be suspected in the presence of:
1 or more of the clinical presentations in Table 4, with or without ancillary features (see below), and
1 or more of the diagnostic criteria from different categories (I to IV) in Table 4
or
when the patient is asymptomatic, 2 or more diagnostic criteria from different categories (I to IV).

Ancillary features which support the clinical suspicion of myocarditis include:
• Fever ≥38°C at presentation or within the preceding 30 days with or without evidence of a respiratory (chills, headache, muscle aches, general malaise) or gastrointestinal (decreased appetite, nausea, vomiting, diarrhoea) infection;
• Peri-partum period;
• Previous clinically suspected or definite myocarditis (according to the criteria set in Table 4);
• Personal and/or family history of allergic asthma, other types of allergy, extra-cardiac autoimmune disease, toxic agents;
• Family history of DCM, myocarditis (according to the present criteria).

**Recommendations**

10. All patients with clinically suspected myocarditis should be considered for selective coronary angiography and EMB.

**Figure 3** The flow chart shows the proposed diagnostic approach for patients with clinically suspected myocarditis according to Table 4.
6.3. Second line tests in patients with a clinical presentation consistent with myocarditis

6.3.1 Endomyocardial biopsy (EMB) - Key points 1

- EMB confirms the diagnosis and identifies the underlying aetiology and the type of inflammation (e.g. giant cell myocarditis, eosinophilic myocarditis, sarcoidosis), which imply different treatments and prognosis (Figure 1). EMB is also the basis for safe (infection negative) immunosuppression and antiviral treatment.
- If EMB is performed by experienced teams, its complication rate is low (0–0.8%).
- Immunohistochemistry and viral genome analysis should be used to achieve an aetiological diagnosis.
- To optimize diagnostic accuracy and reduce sampling error in focal myocarditis, EMB should be performed early in the course of the disease and multiple specimens should be taken. At least three samples, each 1–2 mm in size, should be taken (from the right or from the left ventricle) and immediately fixed in 10% buffered formalin at room temperature for light microscopy; additional samples should be snap frozen in liquid nitrogen and stored at -80°C or stored in RNA later tubes at room temperature for viral PCR.
- To increase the diagnostic sensitivity of immunohistochemistry, use of a large panel of monoclonal and polyclonal antibodies (including anti-CD3, T lymphocytes; anti-CD68, macrophages; and anti HLA-DR) is mandatory for the identification and characterization of the inflammatory infiltrate.
- The diagnostic contribution of EMB is enhanced by molecular analysis with DNA–RNA extraction and RT-PCR amplification of viral genome. In order to exclude systemic infection, peripheral blood should be investigated in parallel with EMB. Suggested primer sets and PCR protocols are detailed below.
Suggested PCR primers and protocols for viral (RT-) qPCR

List of PCR primers in relation to virus type (below) and protocols (shown in Table at the bottom) (continues)

Cytomegalovirus: Size amplicon: 362 bp

5'-Primer / 20 – mer: 5' – gTT  CTC TCg TCT CCT CCg Tg
3'-Primer/ 20 – mer: 5' – CCT gTg gAg CTC gTT AgA gg

Probe: / 26-mer : 5' - DIG. CgA AAA CAT CCA ggg AAA ATg TCg gT


Epstein-Barr-Virus: Size amplicon: 294 bp

5'-Primer / 18 – mer: 5’ – gAg ggT ggT TTg gAA AgC
3'-Primer / 22 – mer: 5’ – AAC AgA CAA Tgg ACT CCC TTA g

FAM - Probe QPCR: 31 – mer: 5' - 6FAM- AAg gAg gTT CCA ACC CgA AAT TTg AgA ACA XT—PH


Suggested PCR primers and protocols for viral (RT-) qPCR

List of PCR primers in relation to virus type (below) and protocols (shown in Table at the bottom) (continues)

Parvovirus B 19: Size amplicon: 249 bp
5'-Primer / 20 – mer: 5’ – gAT ACT CAA CCC CAT ggA gA
3'-Primer / 22 – mer: 5’ – gCC CTA ACA CAT ATg ggT ACT T
FAM - Probe QPCR: 29 – mer: 5’- 6FAM – CTA CTA ACA TgC ATA ggC gCC CTg TAg T XT p


Human herpes virus-6 (HHV-6 A + B): Size amplicon: 607 bp
5'-Primer/ 23 – mer: 5’ – TAA gAT gTA TgC TgA AgA ACG Tg
3'-Primer/ 19 – mer: 5’ – gCT TgT CTT CgT CgT TTC g
Probe: / 29-mer: 5’ – DIG. CCC AAT ATC CAC CgT Tag AgA ACC CAT Tg
### Suggested protocols for viral (RT-) qPCR

<table>
<thead>
<tr>
<th>PCR</th>
<th>RT</th>
<th>PCR activation</th>
<th>Temperatures and Times</th>
<th>Final Extension</th>
<th>Storage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>°C</td>
<td>°C</td>
<td>°C</td>
<td>°C</td>
<td>°C</td>
</tr>
<tr>
<td>Enteroviruses</td>
<td>50</td>
<td>95</td>
<td>15'</td>
<td>94</td>
<td>60</td>
</tr>
<tr>
<td>Influenza A virus</td>
<td>50</td>
<td>95</td>
<td>15'</td>
<td>94</td>
<td>67</td>
</tr>
<tr>
<td>Adenoviruses</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
</tr>
<tr>
<td>Epstein-Barr virus</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
</tr>
<tr>
<td>Parvovirus B19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
</tr>
<tr>
<td>HHV6</td>
<td>94</td>
<td>94</td>
<td>45''</td>
<td>72</td>
<td>1'</td>
</tr>
</tbody>
</table>
6.2 Endomyocardial biopsy (EMB) - Key points 2

The main technical requirements viral RT-PCR are as follows:

- RT-PCR detection of viral DNA or RNA in the heart should always be controlled by amplifying adequate positive samples containing different viral copy numbers as well as negative controls.
- Sequencing of the amplified viral gene product is mandatory in order to identify virus subtypes and recognize contaminations.
- Blood samples should be tested by RT-PCR to detect acute systemic virus infection, and to exclude persistently/latently infected blood cells which might contaminate heart tissue samples but do not indicate virus infection of the myocardium.
- The detection of replicative forms of viral nucleic acids in the heart supports a pathogenic role of virus in myocarditis; however, detection of viral mRNA by RT-PCR may be difficult to establish in EMB due to low amounts of viral mRNA especially in longstanding chronic myocarditis.

6.2 Endomyocardial biopsy (EMB)

**Recommendations**

11. Tissue obtained from EMB should be analysed using histology, immunohistochemistry, and viral PCR (on heart tissue and a blood sample).

12. At least three myocardial samples, each 1–2 mm in size, should be taken (from the right or from the left ventricle) and immediately fixed in 10% buffered formalin at room temperature for light microscopy; additional samples should be taken, snap frozen in liquid nitrogen, and stored at -80°C, or stored in RNA later tubes at room temperature, for viral PCR.

13. Endomyocardial biopsy may be repeated if necessary to monitor response to aetiology-directed therapy, or if a sampling error is suspected in a patient with unexplained progression of heart failure.
7. Clinical management
7.1 Prognostic factors

• Outcome and prognosis of myocarditis depends on aetiology, clinical presentation, and disease stage.
• Acute myocarditis resolves in about 50% of cases in the first 2–4 weeks, but about 25% will develop persistent cardiac dysfunction and 12–25% may acutely deteriorate and either die or progress to end-stage DCM with a need for heart transplantation.
• Biventricular dysfunction at presentation has been reported as the main predictor of death or transplantation.
• Fulminant myocarditis is said to differ from (sub)acute lymphocytic myocarditis in its mode of onset, degree of haemodynamic compromise, and better outcome, but data are relatively scarce in adults. Fulminant myocarditis of unknown aetiology is more frequent in children and prevalent in neonates with a dismal prognosis.
• Most studies suggest that survival rates in giant-cell myocarditis are markedly worse.
• Molecular detection techniques for viral genome in EMB specimens have provided conflicting prognostic information. Viral persistence in the myocardium has been associated with ventricular dysfunction and viral genome clearance with improvement of ventricular function and a better 10-year prognosis. In contrast, in a recent report, immunohistological evidence of inflammation but not the presence of viral genome alone was an independent predictor of survival.

7.1.1 Conventional medical treatment

As large multicentre randomized controlled trials examining distinct pathogenic subsets are not available, recommendations are based on the consensus of the expert Task Force. The core principles of treatment in myocarditis are optimal care of arrhythmia and of heart failure and, where supported by evidence, aetiology-targeted therapy.
a) Haemodynamically unstable patients
These patients should be managed promptly according to current ESC guidelines for heart failure in intensive care units with respiratory and mechanical cardio-pulmonary support facilities. In acute/fulminant cases with cardiogenic shock and severe ventricular dysfunction, ventricular assist devices or extracorporeal membrane oxygenation (ECMO) may be needed to provide a bridge to transplant or to recovery. Because of its simplicity and effectiveness, ECMO therapy can rescue this group of patients

**Recommendations**

14. Patients with a life-threatening presentation should be sent to specialized units with capability for haemodynamic monitoring, cardiac catheterization, and expertise in EMB.

15. In patients with haemodynamic instability, a mechanical cardio-pulmonary assist device may be needed as a bridge to recovery or to heart transplantation.

16. Cardiac transplantation should be deferred in the acute phase, because recovery may occur, but can be considered for haemodynamically unstable myocarditis patients, including those with giant cell myocarditis, if optimal pharmacological support and mechanical assistance cannot stabilize the patient.

b) Haemodynamically stable patients

- When myocarditis is suspected in asymptomatic or mildly symptomatic patients according to the criteria shown in Table 4, admission to hospital and clinical monitoring are recommended until a definite diagnosis is established, since the situation can evolve rapidly and a cardiopulmonary emergency (e.g. severe heart block or life-threatening arrhythmia) is possible and unpredictable, even if systolic function is initially preserved.
- Exercise testing is contraindicated in the acute stage as it can precipitate arrhythmia.
• Patients with haemodynamically stable heart failure should be treated with diuretics, angiotensin-converting enzyme inhibitor, or angiotensin receptor blockade and beta-adrenergic blockade. In patients who have persistent heart failure symptoms despite optimal management, additional treatment with aldosterone antagonists should be considered.
• The procedure for weaning of heart failure therapy following recovery of ventricular function is not defined.
• Non-steroidal anti-inflammatory drugs, in particular acetylsalicylic acid, are a cornerstone of treatment for acute pericarditis, but have been associated with increased mortality in experimental models of myocarditis. Clinical data for their administration in myocarditis are inconclusive, and controlled trials are needed.

**Recommendation**
17. Management of ventricular dysfunction should be in line with current ESC guidelines on heart failure.

c) Arrhythmia
Management of arrhythmia should be in line with current ESC guidelines. Sinus bradycardia, prolonged QRS duration, increased left ventricular hypokinesis on echocardiography, persistent or fluctuating cardiac troponin levels may precede a life-threatening arrhythmia. Temporary pacing may be needed for complete atrio-ventricular block. Indication for cardioverter defibrillator implantation (ICD) is controversial, because myocarditis may heal completely. Bridging by a lifevest in patients with myocarditis and severe ventricular arrhythmia (ventricular tachycardia or fibrillation) could solve the transient problem.

**Recommendations**
18. ICD implantation should be deferred until resolution of the acute episode.
19. Arrhythmia management outside the acute phase should be in line with current ESC guidelines on arrhythmia and device implantation.
d) Avoidance of exercise
Physical activity should be restricted during the acute phase of myocarditis until the disease has completely resolved. Athletes should be temporarily excluded from competitive and amateur leisure time sport activity regardless of age, gender, severity of symptoms, or therapeutic regimen. After resolution of the clinical presentation (at least 6 months after the onset of the disease), clinical reassessment is indicated before the athlete resumes competitive sport. Pre-participation screening should be performed every 6 months during the follow-up. Although the duration of restricted physical activity in non-athletes is undefined, based upon expert opinion of this Task Force, it seems reasonable to give similar recommendations.

Recommendation
20. Physical activity should be restricted during the acute phase of myocarditis and for at least 6 months in athletes and nonathletes. This recommendation is based upon expert opinion of this Task Force.

7.2 Immunomodulatory treatment
a) Anti-viral therapies
• There is still no approved antiviral-therapy for the treatment of enteroviral infections. Vaccines may be an option in the future.
• Treatment with acyclovir, gancyclovir, and valacyclovir may be considered in patients with herpes virus infection, although their efficacy is unproven in myocarditis.
• Preliminary data on interferon beta treatment suggest that it eliminates enteroviral and adenoviral genomes in patients with left ventricular dysfunction, is associated with improvement in NYHA functional class, and, specifically in enteroviral infection, with a better 10-year prognosis. In general, involvement of infectious disease specialists is recommended when deciding on the use of specific antiviral therapies.
b) High dose intravenous immunoglobulin
• High dose intravenous immunoglobulin (IVIG) modulates the immune and inflammatory response by a variety of mechanisms and is used in a number of systemic autoimmune diseases. Its use has been associated with improved left ventricular ejection fraction in chronic symptomatic heart failure of various causes, but IVIG was ineffective in the IMAC controlled trial of recent-onset DCM in which only 15% of patients had biopsy-proven myocarditis of non-specified cause.
• IVIG has no major side effects and may be used in myocarditis refractory to conventional heart failure therapy, both viral and autoimmune forms, particularly if autoantibody-mediated.

7.3 Immunosuppressive therapy
• Most data on safety and efficacy of immunosuppressive regimes in myocarditis have been obtained using steroids alone, azathioprine and steroids, or cyclosporine A, azathioprine and steroids. Information on other drugs is not available. Data from the few randomized clinical trials of immunosuppression in myocarditis and DCM are shown in Table 6.
• Response to therapy is reported mainly in chronic virus-negative forms, in giant cell myocarditis, and in active myocarditis defined as autoimmune (e.g. virus-negative and autoantibody positive). Conversely, immunosuppression had a neutral effect in the Myocarditis Treatment Trial, where patients had myocarditis of unknown aetiology.
• It is necessary to identify possible drugs causing hypersensitivity reactions, particularly in patients with hypereosinophilia; the inducing drug (Table 1) should not be reintroduced after recovery.
• Recently, a single-centre controlled trial, the TIMIC trial, suggested a beneficial effect of combined steroid and azathioprine therapy in virus-negative myocarditis. These data need to be confirmed in multicenter studies.
## Table 6 Controlled immusuppression trials in myocarditis and dilated cardiomyopathy

<table>
<thead>
<tr>
<th>Trial</th>
<th>Year</th>
<th>Type</th>
<th>Pts (n)</th>
<th>Diagnosis</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Authorref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone trial for DCM</td>
<td>1989</td>
<td>Randomized controlled trial (RCT): prednisone (PDN)</td>
<td>102</td>
<td>‘Reactive’ DCM (n = 60) ‘Nonreactive DCM’ (n = 42)</td>
<td>Either higher LV ejection fraction (LVEF) at 3 months or lower LV end-diastolic dimension and better exercise tolerance</td>
<td>Favourable</td>
<td>Parrillo176</td>
</tr>
<tr>
<td>MTT</td>
<td>1995</td>
<td>RCT: PDN and cyclosporine or azathioprine</td>
<td>111</td>
<td>Acute biopsy-proven myocarditis (unknown aetiology)</td>
<td>LVEF at 6 months</td>
<td>Neutral</td>
<td>Mason6</td>
</tr>
<tr>
<td>Giant cell myocarditis treatment trial</td>
<td>2008</td>
<td>Prospective: PDN and cyclosporine</td>
<td>11</td>
<td>Giant cell myocarditis (autoimmune)</td>
<td>Survival at 1 year</td>
<td>Favourable</td>
<td>Cooper99</td>
</tr>
<tr>
<td></td>
<td>2013</td>
<td>Prospective: PDN and azathioprine</td>
<td>41</td>
<td>Active myocarditis and chronic heart failure (aetiology known in retrospect)</td>
<td>LVEF at 1 year</td>
<td>Favourable in virus-negative aabs-positive</td>
<td>Frustaci100</td>
</tr>
<tr>
<td></td>
<td>2001</td>
<td>RCT: PDN and azathioprine</td>
<td>84</td>
<td>Inflammatory DCM (unknown aetiology, increased HLA expression on EMB)</td>
<td>LVEF at 3 months, sustained at 2 years</td>
<td>Favourable</td>
<td>Wojnicz103</td>
</tr>
</tbody>
</table>
7.3 Immunosuppressive therapy - Key messages

**Recommendations**

21. Immunosuppression should be started only after ruling out active infection on EMB by PCR.

22. Based on experience with non-cardiac autoimmune disease, the task group recommends consideration of immunosuppression in proven autoimmune (e.g. infection negative) forms of myocarditis, with no contraindications to immunosuppression, including giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis and myocarditis associated with known extra-cardiac autoimmune disease.

23. Steroid therapy is indicated in cardiac sarcoidosis in the presence of ventricular dysfunction and/or arrhythmia and in some forms of infection-negative eosinophilic or toxic myocarditis with heart failure and/or arrhythmia.

24. Immunosuppression may be considered, on an individual basis, in infection-negative lymphocytic myocarditis refractory to standard therapy in patients with no contraindications to immunosuppression.

25. Follow-up EMB may be required to guide the intensity and the length of immunosuppression.
8. Follow-up
Myocarditis patients can have partial or full clinical recovery; some may relapse many years after the first episode. Relapses should be managed similarly to the index episode. In patients who do not resolve, disease may continue subclinically and lead to DCM.

The myocarditis patient with pseudo-infact presentation, normal coronary arteries, and preserved ventricular function should be discharged when cardiac enzymes have come into the normal range, and offered long-term non-invasive cardiological follow-up. In the event of prolonged (weeks or even months) documented increase of cardiac enzymes, and/or progressive reduction in left and/or right ventricular function, the patient should be readmitted to hospital to perform EMB. Persistently elevated troponin T values could be due to heterophile antibodies interfering with the assay. Performing a troponin I could clarify whether persistent enzyme elevations are due to an analytic error or cardiac pathology. Similarly, chronic skeletal muscle disease could be associated with persistently elevated low level cardiac troponins.

**Recommendations**
26. All patients with myocarditis should be followed, with clinical assessment, ECG, and echocardiography.
27. Long-term follow-up for patients that have experienced myocarditis is recommended.
Authors and Task Force members

Alida L. P. Caforio1,*, Sabine Pankuweit2, Eloisa Arbustini3, Cristina Basso4, Juan Gimeno-Blanes5, Stephan B. Felix6, Michael Fu7, Tiina Helio8, Stephane Heymans9, Roland Jahns10, Karin Klingel11, Ales Linhart12, Bernhard Maisch2, William McKenna13, Jens Mogensen14, Yigal M. Pinto15, Arsen Ristic16, Heinz-Peter Schultheiss17, Hubert Seggewiss18, Luigi Tavazzi19, Gaetano Thiene4, Ali Yilmaz20, Philippe Charron21, and Perry M. Elliott13

1 Division of Cardiology, Department of Cardiological Thoracic and Vascular Sciences, University of Padua, Padova, Italy;
2 Universitätsklinikum Gießen und Marburg GmbH, Standort, Marburg, Klinik für Kardiologie, Marburg, Germany;
3 Academic Hospital IRCCS Foundation Policlinico, San Matteo, Pavia, Italy;
4 Cardiovascular Pathology, Department of Cardiological Thoracic and Vascular Sciences, University of Padua, Padova, Italy;
5 Servicio de Cardiología, Hospital U. Virgen de Arrixaca Ctra. Murcia-Cartagena s/n, El Palmar, Spain;
6 Medizinische Klinik B, University of Greifswald, Greifswald, Germany;
7 Department of Medicine, Heart Failure Unit, Sahlgrenska Hospital, University of Göteborg, Göteborg, Sweden;
8 Division of Cardiology, Helsinki University Central Hospital, Heart & Lung Centre, Helsinki, Finland;
9 Center for Heart Failure Research, Cardiovascular Research Institute, University Hospital of Maastricht, Maastricht, The Netherlands;
10 Department of Internal Medicine, Medizinische Klinik und Poliklinik I, Cardiology, Wuerzburg, Germany;
11 Department of Molecular Pathology, University Hospital Tübingen, Tübingen, Germany;
12 2nd Department of Internal Medicine, 1st School of Medicine, Charles University, Prague 2, Czech Republic;
13 The Heart Hospital, University College, London, UK;
14 Department of Cardiology, Odense University Hospital, Odense, Denmark;
15 Department of Cardiology (Heart Failure Research Center), Academic Medical Center, Amsterdam, The Netherlands;
16 Department of Cardiology, Clinical Center of Serbia and Belgrade University School of Medicine, Belgrade, Serbia;
17 Department of Cardiology and Pneumology, Charité Centrum I (Cardiovascular Medicine), Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany;
18 Medizinische Klinik I, Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany;
19 GVM Care and Research, Maria Cecilia Hospital, Cotignola, RA, Italy;
20 Robert-Bosch-Krankenhaus, Stuttgart, Germany; and
21 UPMC Univ Paris 6, AP-HP, Hôpital Pitié-Salpêtrière, Centre de Référence Maladies cardiaques héréditaires, Paris, France

† A.L.P.C. and S.P. contributed equally to the document.